Proteases
Proteases, also known as peptidases or proteolytic enzymes, consists of a large number of enzymes catalyzing the hydrolysis of peptide bonds and subsequently resulting in the degradation of protein substrates into amino acids. Proteases are involved in a wide range of human diseases, including cancer, neurodegenerative disorders, inflammatory diseases and cardiovascular diseases. Thus numerous proteases inhibitors (small molecules and proteins) have been identified to block activity of proteases. Proteases inhibitors can be classified into different types based on the class of proteases they inhibit through two general mechanisms, irreversible “trapping” reactions and reversible tight-binding reactions. Proteases inhibitors have been used as diagnostic or therapeutic agents for the treatment of proteases-related diseases.
-
B4950 Darunavir EthanolateSummary: nonpeptidic HIV protease inhibitor
-
A3261 BoceprevirSummary: HCV protease inhibitor,potent and selective
-
A3284 Cathepsin S inhibitor1 CitationTarget: CathepsinsSummary: Blocks MHCII antigen presentation
-
A3334 CTS-1027Summary: MMPs inhibitor
-
A3345 Dabigatran etexilate mesylateSummary: Direct thrombin inhibitor,anticoagulant,prodrug of dabigatran
-
A3346 Dabigatran ethyl esterSummary: Thrombin activity inhibitor
-
A3381 EdoxabanTarget: Factor XaSummary: Factor Xa inhibitor
-
A3383 Edoxaban tosylate monohydrateSummary: Oral factor Xa inhibitor
-
A3421 Fosamprenavir Calcium SaltSummary: Prodrug of antiretroviral protease inhibitor amprenavir
-
A3424 Gambogic AcidSummary: Caspase activator and apoptosis inducer